home / stock / immx / immx quote
Last: | $2.19 |
---|---|
Change Percent: | -1.81% |
Open: | $2.25 |
Close: | $2.19 |
High: | $2.33 |
Low: | $2.18 |
Volume: | 63,897 |
Last Trade Date Time: | 04/19/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.19 | $2.25 | $2.19 | $2.33 | $2.18 | 63,897 | 04-19-2024 |
$2.21 | $2.51 | $2.21 | $2.55 | $2.2 | 189,390 | 04-18-2024 |
$2.5 | $2.66 | $2.5 | $2.73 | $2.04 | 516,397 | 04-17-2024 |
$2.57 | $2.61 | $2.57 | $2.68 | $2.525 | 238,899 | 04-16-2024 |
$2.66 | $2.79 | $2.66 | $2.84 | $2.6502 | 95,386 | 04-15-2024 |
$2.76 | $2.83 | $2.76 | $2.88 | $2.625 | 134,028 | 04-12-2024 |
$2.89 | $2.86 | $2.89 | $2.93 | $2.7301 | 119,266 | 04-11-2024 |
$2.88 | $2.81 | $2.88 | $2.9 | $2.727 | 112,957 | 04-10-2024 |
$2.84 | $2.85 | $2.84 | $2.95 | $2.79 | 213,236 | 04-09-2024 |
$2.86 | $2.99 | $2.86 | $2.99 | $2.61 | 102,171 | 04-08-2024 |
$2.87 | $2.78 | $2.87 | $2.94 | $2.7 | 72,433 | 04-05-2024 |
$2.81 | $3.06 | $2.81 | $3.06 | $2.74 | 161,427 | 04-04-2024 |
$3.06 | $2.88 | $3.06 | $3.13 | $2.87 | 88,643 | 04-03-2024 |
$2.94 | $2.86 | $2.94 | $3.02 | $2.78 | 48,386 | 04-02-2024 |
$2.92 | $3.06 | $2.92 | $3.102 | $2.73 | 281,314 | 04-01-2024 |
$3.07 | $3.04 | $3.07 | $3.23 | $3 | 94,564 | 03-29-2024 |
$3.07 | $3.04 | $3.07 | $3.23 | $3 | 94,564 | 03-28-2024 |
$3.07 | $3 | $3.07 | $3.155 | $2.9967 | 48,934 | 03-27-2024 |
$2.94 | $3.11 | $2.94 | $3.19 | $2.87 | 104,132 | 03-26-2024 |
$3.19 | $3.28 | $3.19 | $3.3528 | $3.06 | 118,433 | 03-25-2024 |
News, Short Squeeze, Breakout and More Instantly...
Immix Biopharma Inc. Company Name:
IMMX Stock Symbol:
NASDAQ Market:
Scheduling U.S. site initiation visits April and May 2024 On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New York City lead site and other leading U.S. sites mid-2024 No change in patient enrollment timing LOS ANGELES, April 18, 2024 (GLOBE NEWSWI...
Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory AL amyloidosis will be presented in Baltimore May 7-11, 2024 LOS ...
Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory AL amyloidosis will be presented in Baltimore May 7-11, 2024 LOS ANGELES, April 15, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We...